As featured in As featured in
Wegovy Alternative

Wegovy vs. Linux Health: How do they compare?

Wegovy (semaglutide 2.4mg) is a GLP-1 receptor agonist. Here's how it stacks up against our next-generation dual-agonist treatment — and why patients are switching.

Board-certified physiciansNo insurance required15,000+ patients treated
Medically reviewed by Dr. Rachel Morrison, MD, ABOM · Updated July 2026
22.5% avg weight loss 94% muscle retained $249/mo all-inclusive 4.9/5 patient rating

Side-by-side comparison

Wegovy Linux Health
Avg. weight loss~15%22.5%
MechanismGLP-1 receptor agonistDual GLP-1/GIP
Lean muscle retained~70%94%
Nausea rate~44% nausea~8%
Monthly cost$1,349/moFrom $249/mo
DosingOnce-weekly injectionOnce weekly injection
Insurance requiredUsually yesNo
Physician oversightVaries by providerIncluded + unlimited messaging

Comparison based on published clinical trial data and retail pharmacy pricing. Individual results vary.

About Wegovy

What is Wegovy?

Wegovy (semaglutide 2.4mg) is a GLP-1 receptor agonist manufactured by Novo Nordisk, specifically approved for chronic weight management. It was FDA-approved in 2021 and is administered as a once-weekly injection.

Wegovy was the first GLP-1 medication specifically approved for weight loss (as opposed to diabetes). It contains semaglutide at a higher dose (2.4mg) than Ozempic (up to 2mg). While effective, it targets only the GLP-1 receptor — missing the GIP pathway that dual-agonists activate for superior results.

  • Single-receptor vs. dual-receptor mechanism
  • Higher nausea rates (~44% vs ~8%)
  • Less muscle preservation (~70% vs 94%)
  • Retail price $1,349/mo at pharmacy
  • Pharmacy and manufacturer markups
  • Limited physician oversight at most providers

Why patients switch to Linux Health

Better results: 22.5% average weight loss vs. ~15% with Wegovy, with 94% lean muscle retention.

Lower cost: From $249/mo all-inclusive vs. $1,349/mo at retail pharmacy. No insurance required, no prior authorization.

Better support: Dedicated physician, unlimited messaging, monthly check-ins, dosage optimization — all included in your plan.

Individual results vary. Treatment prescribed only if clinically appropriate.

See if you qualify for a better alternative

Free 5-minute screening. Board-certified physician review. No insurance needed.

Check my eligibility →

No commitment required · Cancel anytime · Starts at $249/mo

Common questions about Wegovy

Can I switch from Wegovy to Linux Health?
Yes. Many of our patients have switched from Wegovy and other GLP-1 medications. Your Linux Health physician will review your current treatment history and create a transition plan. There may be a brief overlap period as dosing is adjusted.
Why is Linux Health cheaper than Wegovy?
Wegovy pricing reflects manufacturer list prices, pharmacy markups, and pharmacy benefit manager fees. Linux Health eliminates these middlemen with direct physician-to-patient prescribing through licensed pharmacy partners at wholesale pricing.
Is the Linux Health medication the same as Wegovy?
No. Wegovy contains semaglutide 2.4mg, a glp-1 receptor agonist. Linux Health prescribes a dual GLP-1/GIP receptor agonist — a next-generation medication that activates both pathways simultaneously for greater weight loss and better muscle retention.
Do I need a prescription to switch?
Yes. Complete our free 5-minute screening and a board-certified physician will evaluate whether our treatment is right for you. If you're currently on Wegovy, share this with your physician during screening — it helps them create the best transition plan.
22.5% average weight loss — outperforms single-receptor drugs

Ready to try a better alternative?

Free 5-minute screening. No insurance required. See if you qualify today.

Start my free screening →
No credit card required Cancel anytime Only pay if approved
15,000+ patients treated nationwide
Start Free Screening →
Wait — before you go

Still deciding? We get it.

Take a free 5-minute screening — no credit card, no commitment. Just honest answers about whether GLP-1 treatment could work for you.

Take the free screening → No thanks, maybe later